The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bausch Health.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, shareholders of DURECT will receive $1.75 per share in cash, representing approximately $63 million upfront with potential milestone payments of up to $350 million. The potential milestone payments are tied to net sales achievements before December 31, 2045.

DURECT insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for DURECT by imposing a significant penalty if DURECT accepts a competing bid. We are investigating the conduct of the DURECT board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250729171780/en/